Methods of treating severe acute respiratory syndrome
AssigneeEagle Pharmaceuticals, Inc.
InventorAdrian Hepner
Life of this patent
Estimating the term…
Abstract
The disclosure is directed to methods of using dantrolene or a dantrolene prodrug, or a pharmaceutically acceptable salt thereof, to treat Severe Acute Respiratory Syndrome.
Claims24
A method of treating Severe Acute Respiratory Syndrome in a subject comprising administering to the subject dantrolene or a pharmaceutically acceptable salt thereof or by administering a dantrolene prodrug or a pharmaceutically acceptable salt thereof, wherein the dantrolene prodrug is a compound of Formula I:
- wherein R is —P(O)(OH)2 or —P(O)(OR1)(OR2);
- R1 is H, —C1-26alkyl, aryl, C1-6alkC(O)O—C1-26alkyl, —C1alkOC(O)C1-26alkyl, or C1alkOC(O)OC1-26alkyl;
- and R2 is —C1-26alkyl, aryl, C1-6alkC(O)O—C1-26alkyl, —C1alkOC(O)C1-26alkyl, or C1alkOC(O)OC1-26alkyl.
A method for inhibiting replication of SARS-COV in a subject comprising administering to the subject dantrolene, or a pharmaceutically acceptable salt thereof or by administering a dantrolene prodrug or a pharmaceutically acceptable salt thereof, wherein the dantrolene prodrug is a compound of Formula I:
- wherein R is —P(O)(OH)2 or —P(O)(OR1)(OR2);
- R1 is H, —C1-26alkyl, aryl, C1-6alkC(O)O—C1-26alkyl, —C1alkOC(O)C1-26alkyl, or C1alkOC(O)OC1-26alkyl;
- and R2 is —C1-26alkyl, aryl C1-6alkC(O)O—C1-26alkyl, —C1alkOC(O)C1-26alkyl, or C1alkOC(O)OC1-26alkyl.
A method for inhibiting replication of SARS-COV in a host cell, for inhibiting entry of SARS-COV into a host cell, for inhibiting SARS-COV virion maturation in a host cell, or for inhibiting release of SARS-COV from a host cell comprising administering to the host cell dantrolene, or a pharmaceutically acceptable salt thereof or by administering a dantrolene prodrug or a pharmaceutically acceptable salt thereof, wherein the dantrolene prodrug is a compound of Formula I:
- wherein R is —P(O)(OH)2 or —P(O)(OR1)(OR2);
- R1 is H, —C1-26alkyl, aryl, C1-6alkC(O)O—C1-26alkyl, —C1alkOC(O)C1-26alkyl, or C1alkOC(O)OC1-26alkyl;
- and R2 is —C1-26alkyl, aryl, C1-6alkC(O)O—C1-26alkyl, —C1alkOC(O)C1-26alkyl, or C1alkOC(O)OC1-26alkyl.
A method for reducing the infectivity of SARS-COV by administering to a host cell dantrolene, or a pharmaceutically acceptable salt thereof or by administering a dantrolene prodrug or a pharmaceutically acceptable salt thereof, wherein the dantrolene prodrug is a compound of Formula I:
- wherein R is —P(O)(OH)2 or —P(O)(OR1)(OR2);
- R1 is H, —C1-26alkyl, aryl, C1-6alkC(O)O—C1-26alkyl, —C1alkOC(O)C1-26alkyl, or C1alkOC(O)OC1-26alkyl;
- and R2 is —C1-26alkyl, aryl, C1-6alkC(O)O—C1-26alkyl, —C1alkOC(O)C1-26alkyl, or C1alkOC(O)OC1-26alkyl.
Dependencies are inferred from the claim text.